Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV

Jake A. Ruddy, Brian J. Boyarsky, Justin Bailey, Andrew H. Karaba, Jacqueline M. Garonzik-Wang, Dorry L. Segev, Christine Durand, William A. Werbel

Research output: Contribution to journalLetterpeer-review

Abstract

This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two doses, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.

Original languageEnglish (US)
Pages (from-to)2399-2401
Number of pages3
JournalAIDS (London, England)
Volume35
Issue number14
DOIs
StatePublished - Nov 15 2021

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV'. Together they form a unique fingerprint.

Cite this